Journal of Pharmacology and Pharmacotherapeutics最新文献

{"title":"Perspectives of ChatGPT in Pharmacology Education, and Research in Health Care: A Narrative Review","authors":"Chetna R. Patel, Sajal K. Pandya, Brijesh M. Sojitra","doi":"10.1177/0976500x231210427","DOIUrl":"https://doi.org/10.1177/0976500x231210427","url":null,"abstract":"In the era of advanced Open artificial intelligence (AI) technology, the large language model tool known as chat generative pre-training transformer (ChatGPT) is gaining an increasing number of users in various fields such as healthcare, medical education, agriculture, and customer support due to its features like information retrieval, generating human-like conversations, and natural language processing. The purpose of this narrative review is to present the perspectives of ChatGPT in pharmacology and medical education. And highlight the limitations of ChatGPT in these areas and draw the attention of policymakers in healthcare to implement such technologies while taking into consideration ethical issues. To collect information regarding the perspectives of ChatGPT in pharmacology and medical education. And highlight the limitations of ChatGPT in these areas. In health care, it helps in the drug discovery and development process, diagnosis, treatment, counseling, assisting in surgical procedures, pharmacovigilance, pharmacy, and so on. In medical education, this tool plays a crucial role in online tutoring, personalized assistance, grading, improvement in grammar, and so on. Despite the limitations, ChatGPT is helpful in healthcare, medical education, and scientific writing. To overcome such limitations of ChatGPT, like ethical issues, emotionlessness, providing information before 2021, the risk of biases, uncontrollability, lack of transparency, academic dishonesty, and so on, alternatives have been developed, but they also fail to entirely resolve the associated limitations. Looking at the current scenarios, there is an urgent need for comprehensive guidelines to address these limitations and provide a framework for appropriately utilizing AI tools in healthcare domains. This framework should also focus on maintaining a balance between human involvement and technological advancements.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139154928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Various Factors Influencing the Enantiomers of Warfarin Pharmacokinetics: A Systematic Review of Population Pharmacokinetics","authors":"Sirajudeen Mahaboob, G.N.K. Ganesh, K.P. Arun, S.D. Rajendran","doi":"10.1177/0976500x231211401","DOIUrl":"https://doi.org/10.1177/0976500x231211401","url":null,"abstract":"Warfarin is the most commonly prescribed anticoagulant medication. Warfarin’s pharmacokinetics (PK) in its enantiomeric form have been reported to be highly variable. Five population pharmacokinetic model studies for warfarin were identified in this systematic review. This review summarized these studies and reported on various factors affecting warfarin PK. Most studies reported a one-compartment model with first-order absorption and elimination for both S-warfarin and R-warfarin. Warfarin disposition has been reported to be influenced by various factors, including gender, age, genetic variation, body surface area (BSA), concurrent drug, weight, and ethnicity. So, all of these factors must be considered when addressing this pharmacokinetic variability. These models should undergo an external evaluation to confirm their generalizability and to support model-informed dosing in clinical settings.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138996975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Fluoxetine and Escitalopram on Heart Rate Variability (HRV) and Serum Potassium Level in Patients of Depression and Anxiety Disorders","authors":"Truptiben R Machhi, Chetna R. Patel, Sajal K. Pandya, N. Kantharia","doi":"10.1177/0976500x231213153","DOIUrl":"https://doi.org/10.1177/0976500x231213153","url":null,"abstract":"The present study was conducted to generate data regarding the effect of fluoxetine as an anti-depressant and escitalopram as an antianxiety agent on heart rate variability (HRV). There is a scarcity of data regarding the correlation between selective serotonin reuptake inhibitors (SSRIs) and serum potassium levels. To find out the effect of SSRIs on HRV, and whether it is either dependent or independent of serum potassium level. In this prospective, open-label, observational study, 70 participants were enrolled and divided into two groups, the fluoxetine group ( n = 35) and the escitalopram group ( n = 35) suffering from depression and anxiety, respectively. Parameters, like HRV, serum potassium level, heart rate, respiratory rate, and blood pressure, were measured baseline and after the first, second, and third months of treatment. HRV was calculated by root mean square deviation of successive differences between adjacent RR intervals (RMSSD). ECG (electrocardiogram) was recorded by Physio Pac Digital Polygraph software. All values were expressed as mean ± SD, and statistical analysis was done by using the repeated measure analysis of variance (ANOVA) test with Greenhouse–Geisser correction, post-hoc analysis with Bonferroni correction, and SPSS 20.0 software. Among a total of 70 participants, post-hoc tests using the Bonferroni correction showed a statistically significant difference between the HRV of the pretreatment group and after the second, and third month of fluoxetine therapy ( p < .05). In the escitalopram group, the Bonferroni correction showed a significant difference between the HRV of the pretreatment and third-month value ( p < .05). Repeated measure ANOVA with Greenhouse–Geisser correction showed no statistical significance of serum potassium at different time points ( p > .05). There were also no significant changes in heart rate, respiratory rate, and blood pressure at different points of time in both groups. Pearson’s correlation coefficient test for a relationship between HRV and serum potassium was negative at different time points. Fluoxetine significantly increased HRV from the pretreatment value to the second and third months of treatment, whereas in the escitalopram group of participants, the third-month value of HRV was increased compared to the first month. The effect of SSRIs on HRV was independent of serum potassium levels at different time points suggesting that the effect of SSRIs on HRV was independent of serum potassium level.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138999749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antirheumatic and Memory-enhancing Effect of Memantine on Complete Freund’s Adjuvant-induced Rheumatoid Arthritis Compared to Methotrexate in Wistar Rats","authors":"S. Jalgaonkar, Sumith Ourasang, R. Tripathi, Pradeep Vaideeswar, Padma Badhe","doi":"10.1177/0976500x231211394","DOIUrl":"https://doi.org/10.1177/0976500x231211394","url":null,"abstract":"To evaluate the anti-inflammatory and memory-enhancing effects of memantine (MEM) in complete Freund’s adjuvant (CFA)-induced rheumatoid arthritis (RA) in Wistar rats. The effect of MEM on cognition in CFA-induced RA was also evaluated. The rats were randomly assigned to one of five groups: sham control (SC), disease control (DC)—CFA 0.1 mg, positive control (PC)—methotrexate (MTX) 1 mg/kg, low dose MEM—20 mg/kg, and high dose MEM (HD-M)—50 mg/kg. All groups received a subcutaneous injection of CFA in the left paw on day 0, except for the SC group, which received a distilled water (DW) injection. The study drugs, MEM and MTX, were administered orally from days 15 to 28. The SC group received DW orally from days 15 to 28. Variables for physical (paw volume, paw surface temperature, and ankle joint diameter) and behavior (open field test, grip strength test, and water corn test) were performed on days 1, 0, 7, 14, 21, and 28. On day 28, blood was collected for serum inflammatory markers, tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6. Ex vivo radiological changes in the ankle joint were recorded using a digitalized X-ray machine. Histopathology of the ankle joint was performed. When compared to the DC group, the HD-M group showed a significant improvement in all physical and behavioral characteristics ( p < 0.001). When compared to the DC group, TNF-α, IL-6 levels, and histopathological scores were significantly lower in the HD-M group ( p < 0.01). MEM reduces inflammation and improves memory in Wistar rats with CFA-induced RA. MEM can be used as an anti-inflammatory drug in elderly patients at risk of dementia.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139005348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terbinafine-induced Myositis: A Case Report","authors":"Atiqulla Shariff, Vaishakhi Shetty, Muskan Singh, Anjani Kumari, S. Sridhar, Srikanth Malavalli Siddalingegowda","doi":"10.1177/0976500x231214031","DOIUrl":"https://doi.org/10.1177/0976500x231214031","url":null,"abstract":"We report a case of terbinafine-induced myositis in a 37-year-old Asian male patient treated for Tinea cruris. The patient complained of severe generalized body aches, weakness, fever, fatigue, and passing of concentrated urine after consuming one dose of terbinafine 250 mg tablet, which worsened after the second dose. At the presentation, the patient was afebrile, fatigued, and had difficulty moving. All the laboratory parameters were normal, except N-acetyl-cysteine-(NAC)-activated creatine kinase, which was elevated to 276 U/L. There was a slight elevation in alanine transaminase (ALT) levels (44 U/L) and albumin-to-globulin ratio (1.8). The oral terbinafine was stopped. Patient was prescribed with tablet acetaminophen 650 mg thrice daily for two days and as needed thereafter, to manage myalgia. The patient reported being symptomatically better after six days of terbinafine withdrawal. The Naranjo’s causality assessment scale score was eight, indicating a probable relation between drug exposure (terbinafine use) and adverse drug reaction (myositis). The severity of terbinafine-induced myositis in this patient was moderate (level 3) as categorized by the Modified Hartwig and Siegel scale.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139005776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model","authors":"S. T., S. S., Eliz Thomas, Karthika P.","doi":"10.1177/0976500x231213486","DOIUrl":"https://doi.org/10.1177/0976500x231213486","url":null,"abstract":"Non-alcoholic steatohepatitis (NASH) is a clinical condition with a global prevalence of 25.24%. Peroxisome proliferator-activated receptors (PPAR) have been significantly associated with the pathogenesis of NASH. To evaluate the efficacy of saroglitazar in an animal model of NASH by evaluating the magnitude of changes in liver function tests (LFT) and histopathology. The baseline parameters of 14 male Sprague–Dawley rats were recorded and then grouped into four groups: treatment groups (high high-dose saroglitazar [HDSG] and low low-dose saroglitazar [LDSG] doses of saroglitazar), normal control, and disease control. Initially, except for the normal control, the other three groups were fed a fructose diet for 5 weeks and then all four groups were fed a standard chow diet for the next 2 weeks during which the two treatment groups were orally gavaged with saroglitazar. Changes in LFT, body weight (BW), lipid profile, oxidative stress, and histopathology were evaluated at different time points. A statistically significant reduction was found in the mean serum glutamic-oxaloacetic transaminase (SGOT) ( p = 0.0267) and serum glutamate-pyruvate transaminase (SGPT) ( p = 0.0059) between the groups at the end of treatment. As with BW changes ( p < 0.001), a significant difference was observed between the time points in HDSG and LDSG with respect to all parameters of the lipid profile assessed ( p < 0.05). Amelioration of hepatocellular ballooning and lobular inflammation in histopathology was evident in both treatment groups. Immunohistochemistry revealed loss of cytokeratin CK8/18 in disease control while it was preserved in LDSG and HDSG. The study has explicitly illustrated the improvement in the biochemical and pathological changes in the rat model of NASH induced by a high fructose diet.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Antimicrobial Usage in a Secondary Care Hospital in Ras Al Khaimah, United Arab Emirates","authors":"Sarah Dawood, Yasmin Sharifian, Masah Mardini, Duaa Jawhar, Laxminarayana Kurady Bairy, Suresh Kumar Srinivasamurthy","doi":"10.1177/0976500x231203845","DOIUrl":"https://doi.org/10.1177/0976500x231203845","url":null,"abstract":"Objective To assess the pattern of antimicrobial use among pediatric inpatients in a secondary care hospital in the United Arab Emirates. Methods The prospective study was conducted based on the electronic records of 600 patients, collected over a period of 11 months, from September 2020 to July 2021. The primary patient population was the pediatric patients receiving antimicrobials admitted to Saqr Hospital, Ras Al Khaimah (RAK), United Arab Emirates (UAE). The data gathered includes general patient information, lab investigations, diagnoses, chronic medical conditions, and antimicrobials used. The number of defined daily doses (DDDs) administered per patient was calculated for each antimicrobial prescribed as per the WHO anatomical therapeutic chemical classification. Results Out of 1400 patients admitted to the pediatric unit during the 11-month study period, 600 (42.8%) received antimicrobials. The mean duration of hospital stay was 3.44 days, and each patient received a mean of 1.41 antimicrobials per prescription. The mean days of antimicrobial therapy were 6.9 days. The majority of the patients were aged 0–5 years (61.1%), and 58% of the total sample was male. Amongst a total of 41 different antimicrobials prescribed, the beta-lactam co-amoxiclav (J01CR02) was the most frequently (19.3%) used one, followed by cefuroxime (J01DC02) (16.3%), amoxicillin (J01CA04) (15.0%), and azithromycin (J01FA10) (5.99%). These were administered mainly via the parenteral route, and the most common indication was respiratory disease. Conclusion Our study concludes that most of the prescribed antimicrobials for pediatric patients are within the WHO access and watch group. Co-amoxiclav, cefuroxime, and amoxicillin are the most frequently used antimicrobials. The main indication for use was respiratory illness.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135271735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin Exerts a Protective Effect on Ischemic Stroke-induced Memory Deficits in Mice","authors":"Chrismawan Ardianto, Dewi Lestari, Luthfia Hany Primadani, Dwi Retno Puspitasari, I Nengah Budi Sumartha, Khoirotin Nisak, Aniek Setiya Budiatin, Dewi Wara Shinta, Mareta Rindang Andarsari, Farida Ifadotunnikmah, Amar Daud Iskandar Abdullah, Mahardian Rahmadi, Junaidi Khotib","doi":"10.1177/0976500x231189343","DOIUrl":"https://doi.org/10.1177/0976500x231189343","url":null,"abstract":"Objective Brain injury resulting from an ischemic stroke affects cognitive performance by disrupting the hippocampus. Several processes are involved in brain injury progression, including inflammation, glutamate excitotoxicity, and modulated brain peptide systems such as the melanocortin system. Reports show that quercetin exerts neuroprotective activity. This study investigates quercetin’s role in the cognitive function of ischemic stroke-induced mice and the possible mechanisms involved. Method ICR mice were used. The left unilateral common carotid artery occlusion was conducted for 4 h to induce an ischemic stroke in the mice. Quercetin 50, 100, and 200 mg/kg were administered to separate groups intraperitoneally for 7 days. Cognitive function was examined using the T-maze test. The hippocampal mRNA expressions of NR2A, NR2B, melanocortin 4 receptor (MC4R), pro-opiomelanocortin precursors (POMC), and nuclear factor 2 (Nrf2) were examined using reverse transcription-polymerase chain reaction. Results It was found that stroke disrupted cognitive function. Quercetin administration ameliorated cognitive impairment. Quercetin attenuated the stroke-induced decrease in MC4R mRNA expression. Moreover, quercetin suppressed the stroke-induced increase in the hippocampal mRNA expression of NR2A. Conclusion Quercetin ameliorates cognitive deficits and normalizes impaired hippocampal melanocortin and glutamatergic signaling in ischemic stroke-induced mice.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134970869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue Virus: Molecular Biology and Recent Developments in Control Strategies, Prevention, Management, and Therapeutics","authors":"A. Hershan","doi":"10.1177/0976500X231204401","DOIUrl":"https://doi.org/10.1177/0976500X231204401","url":null,"abstract":"Dengue is a viral infection caused by one of four serotypes of dengue virus (DENV), which is responsible for causing potentially life-threatening disease and substantial public health as well as economic burden worldwide. The non-structural and structural proteins of DENV are essential to its viral activity and pathogenesis. Unfortunately, despite numerous efforts, there is still no cure for dengue. Most of the available therapeutic options only provide symptomatic treatment. Since there is a lack of cure and dengue-related substantial economic and public health burden, a safe and effective dengue vaccine is urgently required. Currently, there is only one approved dengue vaccine available that provides suboptimal protection; however, a range of other dengue vaccines are under development to lower the infection burden and decrease dengue morbidities. In addition, numerous dengue therapeutics are also being developed, which have great potential in dengue treatment. These therapeutics mostly act by decreasing viral replication, vascular pathologies, and/or inflammation. This review comprehensively summarizes the latest update on dengue vaccines and therapeutics. Moreover, various other important aspects of DENV, including molecular biology, pathogenesis, and control strategies, have also been discussed.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139371118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Adverse Drug Reactions, Severity, Preventability Status, and Its Determinants among Inpatients in Tertiary Care Hospitals in South India","authors":"","doi":"10.4103/jpp.JPP_74_20","DOIUrl":"https://doi.org/10.4103/jpp.JPP_74_20","url":null,"abstract":"","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141218004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}